Pasithea therapeutics corp. announces closing of $30.4 million private placement priced at a premium to the market under nasdaq rules

Miami beach, fla., nov. 29, 2021 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta; kttaw) (“pasithea” or the “company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under nasdaq rules. the company sold an aggregate of 8.68 million shares of common stock and warrants to purchase 8.68 million shares of common stock at a purchase price of $3.50 per share and accompanying warrant for gross proceeds to the company of $30.4 million, before deducting the placement agent's fees and other estimated offering expenses.
KTTA Ratings Summary
KTTA Quant Ranking